Stockreport

Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Agilent Technologies, Inc.  (A) 
Last agilent technologies, inc. earnings: 2/18 04:05 pm Check Earnings Report
US:NYSE Investor Relations: investor.agilent.com
PDF SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guid [Read more]